
Lilly’s weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
By Bhanvi Satija (Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder. The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company…